Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
NASDAQ:INSM
INSM Analyst Ratings
Strong Buy
15 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
INSM Stock 12 Month Forecast
Average Price Target
$98.00
▲(37.89% Upside)
| Highest Price Target$110.00 | Average Price Target$98.00 | Lowest Price Target$90.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
Reiterated
04/14/25
Cantor Fitzgerald
Reiterated
04/11/25
Guggenheim
Reiterated
04/10/25
Mizuho Securities
Reiterated
04/09/25
RBC Capital
Reiterated
04/03/25
Wells Fargo
Reiterated
03/24/25
Truist Financial
Reiterated
03/21/25
H.C. Wainwright
Reiterated
03/18/25
J.P. Morgan
Reiterated
03/14/25
Morgan Stanley
$90
Buy
26.64%
Upside
Initiated
03/06/25
Insmed's Strategic Growth and Promising Pipeline Drive Buy RatingWe are focusing on the brensocatib launch trajectory and see Insmed as well-positioned to drive meaningful value creation this year through the potential approval and launch in bronchiectasis, as well as data readouts from TPIP and brensocatib.
Leerink Partners
$85→$100
Buy
40.71%
Upside
Reiterated
02/21/25
Insmed (INSM) PT Raised to $100 at Leerink PartnersLeerink Partners analyst Joseph P. Schwartz raised the price target on Insmed (NASDAQ: INSM) to $100.00 (from $85.00) while maintaining a Outperform rating.
Stifel Nicolaus
$97→$96
Buy
35.08%
Upside
Reiterated
02/21/25
Insmed (INSM) Receives a Buy from Stifel Nicolaus
Evercore ISI
$75→$90
Buy
26.64%
Upside
Reiterated
02/07/25
Evercore ISI Sticks to Their Buy Rating for Insmed (INSM)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
Reiterated
04/14/25
Cantor Fitzgerald
Reiterated
04/11/25
Guggenheim
Reiterated
04/10/25
Mizuho Securities
Reiterated
04/09/25
RBC Capital
Reiterated
04/03/25
Wells Fargo
Reiterated
03/24/25
Truist Financial
Reiterated
03/21/25
H.C. Wainwright
Reiterated
03/18/25
J.P. Morgan
Reiterated
03/14/25
Morgan Stanley
$90
Buy
26.64%
Upside
Initiated
03/06/25
Insmed's Strategic Growth and Promising Pipeline Drive Buy RatingWe are focusing on the brensocatib launch trajectory and see Insmed as well-positioned to drive meaningful value creation this year through the potential approval and launch in bronchiectasis, as well as data readouts from TPIP and brensocatib.
Leerink Partners
$85→$100
Buy
40.71%
Upside
Reiterated
02/21/25
Insmed (INSM) PT Raised to $100 at Leerink PartnersLeerink Partners analyst Joseph P. Schwartz raised the price target on Insmed (NASDAQ: INSM) to $100.00 (from $85.00) while maintaining a Outperform rating.
Stifel Nicolaus
$97→$96
Buy
35.08%
Upside
Reiterated
02/21/25
Insmed (INSM) Receives a Buy from Stifel Nicolaus
Evercore ISI
$75→$90
Buy
26.64%
Upside
Reiterated
02/07/25
Evercore ISI Sticks to Their Buy Rating for Insmed (INSM)
Best Analysts Covering Insmed
Which Analyst Should I Follow If I Want to Buy INSM and Sell After:
1 Month
xxx
Success Rate
13/22 ratings generated profit
Average Return
+2.40%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.09% of your transactions generating a profit, with an average return of +2.40% per trade.
3 Months
xxx
Success Rate
14/19 ratings generated profit
Average Return
+29.73%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +29.73% per trade.
1 Year
Success Rate
9/12 ratings generated profit
Average Return
+84.00%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +84.00% per trade.
2 Years
xxx
Success Rate
9/12 ratings generated profit
Average Return
+117.83%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +117.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
INSM Analyst Recommendation Trends
Rating
Nov 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
2
2
2
0
1
Buy
23
37
47
50
38
Hold
0
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
40
50
51
39
Each month's total comprises the sum of three months' worth of ratings.
INSM Financial Forecast
INSM Stock Forecast FAQ
What is INSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Insmed’s 12-month average price target is $98.00.
What is INSM’s upside potential, based on the analysts’ average price target?
Insmed has 37.89% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is INSM a Buy, Sell or Hold?
Insmed has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.
What is Insmed’s price target?
The average price target for Insmed is $98.00. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $90.00. The average price target represents 37.89% Increase from the current price of $71.07.
The highest analyst price target is $110.00 ,the lowest forecast is $90.00. The average price target represents 37.89% Increase from the current price of $71.07.
What do analysts say about Insmed?
Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of INSM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.